Patents by Inventor Wendy Shoop

Wendy Shoop has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GENE EDITING METHODS FOR TREATING ALPHA-1 ANTITRYPSIN (AAT) DEFICIENCY
    Publication number: 20250228973
    Abstract: Disclosed are engineered meganucleases that bind and cleave a recognition sequence within a serine peptidase inhibitor, Clade A, Member 1 (SERPINA1) gene, which encodes alpha-1 antitrypsin (AAT). Further disclosed are donor polynucleotides that encode functional AAT proteins. The present disclosure also encompasses methods of using such engineered meganucleases and donor polynucleotides to make genetically-modified cells and use of such compositions for treatment of AAT deficiency.
    Type: Application
    Filed: October 19, 2022
    Publication date: July 17, 2025
    Inventors: James Jefferson Smith, John Morris, Janel Lape, Cassandra Gorsuch, Paige Scarlett Nemec, Jason Richard Harris, Wendy Shoop
  • GENE EDITING METHODS FOR TREATING ALPHA-1 ANTITRYPSIN (AAT) DEFICIENCY
    Publication number: 20240408235
    Abstract: Disclosed are engineered meganucleases that bind and cleave a recognition sequence within a serine peptidase inhibitor, Clade A, Member 1 (SERPINA1) gene, which encodes alpha-1 antitrypsin (AAT). Further disclosed are donor polynucleotides that encode functional AAT proteins. The present disclosure also encompasses methods of using such engineered meganucleases and donor polynucleotides to make genetically-modified cells and use of such compositions for treatment of AAT deficiency.
    Type: Application
    Filed: October 19, 2022
    Publication date: December 12, 2024
    Inventors: Cassandra Gorsuch, Paige Scarlett Nemec, Jason Richard Harris, Wendy Shoop
  • ENGINEERED MEGANUCLEASES THAT TARGET HUMAN MITOCHONDRIAL GENOMES
    Publication number: 20240200046
    Abstract: Disclosed herein are recombinant meganucleases engineered to recognize and cleave a recognition sequence present in the human mitochondrial DNA (mtDNA). The disclosure further relates to the use of such recombinant meganucleases in combination with mitochondrial transit peptides in methods for producing genetically-modified eukaryotic cells, and to a population of genetically-modified eukaryotic cells wherein the mtDNA has been modified or edited.
    Type: Application
    Filed: April 22, 2022
    Publication date: June 20, 2024
    Applicants: Precision BioSciences, Inc., University of Miami
    Inventors: Carlos T. Moraes, James Jefferson Smith, Derek Jantz, Ginger H. Tomberlin, John Morris, Wendy Shoop
  • COMPOSITIONS AND METHODS FOR GENERATING MALE STERILE PLANTS
    Publication number: 20240141311
    Abstract: Disclosed herein are recombinant meganucleases engineered to bind and cleave a recognition sequence in the mitochondrial DNA (mtDNA) of a eukaryotic cell, such as a plant cell. The disclosure further relates to the use of such recombinant meganucleases in methods for producing genetically-modified eukaryotic cells, and to a population of genetically-modified eukaryotic cells wherein the mtDNA has been having modified or edited.
    Type: Application
    Filed: April 22, 2022
    Publication date: May 2, 2024
    Applicant: North Carolina State University
    Inventors: Ralph Dewey, Derek Jantz, James Jefferson Smith, Ginger H. Tomberlin, John Morris, Anna Matthiadis, Wendy Shoop
  • ENGINEERED MEGANUCLEASES THAT TARGET HUMAN MITOCHONDRIAL GENOMES
    Publication number: 20240084276
    Abstract: Disclosed herein are recombinant meganucleases engineered to recognize and cleave a recognition sequence present in the human mitochondrial DNA (mtDNA). The disclosure further relates to the use of such recombinant meganucleases in methods for producing genetically-modified eukaryotic cells, and to a population of genetically-modified eukaryotic cells wherein the mtDNA has been having modified or edited.
    Type: Application
    Filed: November 21, 2023
    Publication date: March 14, 2024
    Applicants: Precision Biosciences, Inc., University of Miami
    Inventors: James Jefferson Smith, Ginger Tomberlin, John Morris, Wendy Shoop, Carlos T. Moraes
  • Engineered meganucleases that target human mitochondrial genomes
    Patent number: 11866747
    Abstract: Disclosed herein are recombinant meganucleases engineered to recognize and cleave a recognition sequence present in the human mitochondrial DNA (mtDNA). The disclosure further relates to the use of such recombinant meganucleases in methods for producing genetically-modified eukaryotic cells, and to a population of genetically-modified eukaryotic cells wherein the mtDNA has been having modified or edited.
    Type: Grant
    Filed: January 30, 2023
    Date of Patent: January 9, 2024
    Assignees: University of Miami, Precision BioSciences, Inc.
    Inventors: James Jefferson Smith, Ginger Tomberlin, John Morris, Wendy Shoop, Carlos T. Moraes
  • ENGINEERED MEGANUCLEASES THAT TARGET HUMAN MITOCHONDRIAL GENOMES
    Publication number: 20230295590
    Abstract: Disclosed herein are recombinant meganucleases engineered to recognize and cleave a recognition sequence present in the human mitochondrial DNA (mtDNA). The disclosure further relates to the use of such recombinant meganucleases in methods for producing genetically-modified eukaryotic cells, and to a population of genetically-modified eukaryotic cells wherein the mtDNA has been having modified or edited.
    Type: Application
    Filed: January 30, 2023
    Publication date: September 21, 2023
    Inventors: James Jefferson Smith, Ginger Tomberlin, John Morris, Wendy Shoop, Carlos T. Moraes